–News Direct–
Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) CEO Gary Phillips tells Proactive the company is set to undergo a restructure to refocus on developing drugs to treat blood-related cancers. This involves the creation of clinical stage drug development company, Syntara and the sale of its mannitol respiratory business unit, along with changes to the companys board of directors. The move, which will see the company primarily focus on clinical development, will result in a significant reduction in annual costs core expenses are expected to drop by more than 60%, saving the company more than $14 million per year. The company has five planned clinical studies to deliver results in high unmet need diseases by mid-2025.
Phillips said: Over the last few years Pharmaxis has built a commanding position in lysyl oxidase biology and chemistry research. We have collaborated with leading clinicians and scientists worldwide and forged through the early stage studies that have given us a clinical pipeline with great potential and resulted in multiple Nature publications.
Building on this heritage and the proven capability of our discovery and development teams, the restructure announced today and the creation of Syntara enables us to focus and accelerate our clinical development program
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
jonathan@proactiveinvestors.com
View source version on newsdirect.com: https://newsdirect.com/news/pharmaxis-to-focus-on-clinical-stage-drug-development-700712011
Pharmaxis Ltd
COMTEX_441380334/2655/2023-10-03T15:39:50
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Endowment Lock journalist was involved in the writing and production of this article.